Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Adverse effects of immune checkpoint inhibitors in advanced endometrial cancer: A systematic review and meta-analysis.

Fizza Mohsin, Thi Ha Zaw, Jawad Basit et al. Jun 01, 2025 pp. 5610-5610 10.1200/jco.2025.43.16_suppl.5610

5610 Background: Immune checkpoint inhibitors (ICIs) in combination with chemotherapy have become a standard first-line treatment for advanced endometrial...

Racial disparities in incidence and mortality among AYA patients with lung adenocarcinoma and squamous cell carcinoma in the US: A SEER database analysis.

Ben Ponvilawan, Chalothorn Wannaphut, Dhruv Bansal et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13744

e13744 Background: Despite a steady increase in the incidence of adolescent and young adult (AYA) lung cancer in the US, racial disparities involving lung...

Phase II trial of serplulimab combined with gemcitabine plus nab-paclitaxel (GnP) and SBRT for metastatic pancreatic cancer as the first-line treatment.

Ke Cheng, Chenyan Zhang, Gang Zhao et al. Jun 01, 2025 pp. 4160-4160 10.1200/jco.2025.43.16_suppl.4160

4160 Background: The addition of anti-PD-1 monoclonal antibody (mAb) to gemcitabine and nab-paclitaxel (GnP) presented limited improvement in objective re...

Disparities in receipt of palliative treatments among disaggregated Hispanic populations with breast, lung, and prostate cancer in the United States.

Shriya Garg, Khushi Kohli, Isha Garg et al. Jun 01, 2025 pp. 12029-12029 10.1200/jco.2025.43.16_suppl.12029

12029 Background: Despite palliative interventions’ ability to improve the quality of life and possibly improve overall survival, significant inequalities...

Effect of 4-1BBL-OX40L fusion protein on the anti-tumor activity of CAR-T cells in solid tumors.

Na Xian, Jindong Zhang, Dandan Liu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14535

e14535 Background: Chimeric antigen receptor T (CAR-T) cell therapy has shown clinical success in hematologic malignancies but faces challenges in solid t...

Community oncologists' and patients' perspectives on the post-CAR-T care transition: A convergent mixed-methods study.

Aqsa Ashraf, Kira MacDougall, Jennifer Holter Chakrabarty et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23134

e23134 Background: Chimeric antigen receptor T-cell (CAR-T) therapy is administered at accredited centers, with (w/) patients (pts) usually transitioning...

Mesenchymal stromal cells for the prophylaxis of graft-versus-host disease after hematopoietic stem cell transplantation: A meta-analysis of randomized controlled trials.

Muhammad Ayyan, Roshan Afshan, Sushmitha Rameshbabu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18549

e18549 Background: Mesenchymal stromal cells (MSCs) have emerged as a potential alternative therapeutic strategy for the prophylaxis of graft-versus-host...

The influence of MRI scan position using a novel head and neck immobilization device on radical radiotherapy for nasopharyngeal carcinoma.

Wenmin Ying Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18030

e18030 Background: To investigate the influence of MRI scan position on the registration accuracy, gross tumor volume (GTV) delineation, and radiotherapy...

Implementing the ASCO PGA in a remote Australian setting.

Ranjana Srivastava, Lauren Reardon, Tatum Pretorius et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13853

e13853 Background: Hamilton is a remote Australian town of 10,000 residents. With limited access to visiting oncologists, it has become apparent that inte...

RHEA-1: First-in-human (FIH) study of AZD9793, a first-in-class CD8-guided T cell-engager (TCE) for glypican-3-positive (GPC3+) advanced or metastatic hepatocellular carcinoma (HCC).

Stephane Champiat, Patrick Grierson, Jason Chia-Hsun Hsieh et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps4215

TPS4215 Background: GPC3 is an oncofetal protein expressed in 70–80% of HCC and is associated with poor prognosis. Preliminary clinical research on GPC3-s...

A technology-enabled clinical trial program’s impact on patient screening and trial enrollment in 2024.

Samantha Mallahan, Danielle Skelly, Michelle Huang et al. Jun 01, 2025 pp. 1506-1506 10.1200/jco.2025.43.16_suppl.1506

1506 Background: Typical workflows for clinical trial start-up and screening are time- and resource-intensive. The Tempus AI TIME program offers a novel c...

Multigene NGS assay for biomarker identification in 621 colorectal cancer cases.

Athanasios Kotsakis, Eleni Thanou, Maria Vlachou et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15168

e15168 Background: Colorectal cancer (CRC), a major cause of cancer-related mortality, is driven by diverse genetic and molecular alterations. Advances in...

Clinical value of carbon nanoparticle staining in identifying metastatic lymph nodes in colorectal cancer surgery.

Bingjun Bai, Zhangfa Song, Li Chen Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15564

e15564 Background: Carbon nanoparticles (CNPs) are increasingly used to trace lymph nodes (LNs) in colorectal cancer (CRC) surgery. However, the relations...

AI-based predictive tool for detection of ctDNA in pancreatic adenocarcinoma using nationwide comprehensive genomic profiling data.

Hiroaki Ikushima, Kousuke Watanabe, Aya Shinozaki-Ushiku et al. Jun 01, 2025 pp. 4163-4163 10.1200/jco.2025.43.16_suppl.4163

4163 Background: Comprehensive genomic profiling (CGP) has become a cornerstone of precision oncology, with liquid biopsy expanding its applicability. How...

Comprehensive longitudinal immune cell monitoring in patients with extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy to predict early relapse.

Seren Durer, Patricia A. Rayman, Peronne Joseph et al. Jun 01, 2025 pp. 8096-8096 10.1200/jco.2025.43.16_suppl.8096

8096 Background: Small cell lung cancer (SCLC) is characterized by rapid growth, and although initial chemo-immunotherapy achieves high response rates, re...

Multiomic profiling of LRRC15 in triple negative breast cancer (TNBC).

Dan Morgenstern Kaplan, Sachin Kumar Deshmukh, Sharon Wu et al. Jun 01, 2025 pp. 1098-1098 10.1200/jco.2025.43.16_suppl.1098

1098 Background: Leucine-rich repeat-containing protein 15 ( LRRC15) has emerged as a potential biomarker and therapeutic target f...

Integration of next-generation RNA sequencing-based MammaPrint and BluePrint analysis in clinical decision making: Performance evaluation in the first 1095 cases.

Christos Poulios, Sara Vander Borght, Sofie Claerhout et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12523

e12523 Background: Currently, multigene signatures (MGS) such as MammaPrint and BluePrint (MP/BP) have become a cornerstone for selecting breast cancer pa...

Caregiver distress: Caring for those who care for our patients.

Abigail Smith Zamorano, Joe Haydamous, Jorge Cervantes et al. Jun 01, 2025 pp. 11115-11115 10.1200/jco.2025.43.16_suppl.11115

11115 Background: Gynecologic cancers cause high physical and psychosocial strain, worsened by unmet social determinants of health (SDOH) in cancer care....

Impact of anti-EGFR and anti-VEGF antibodies on survival in BRAF <sup>V600E</sup> mutated metastatic colorectal cancer: A pooled analysis of eight clinical trials performed in the first-line treatment of mCRC (German AIO Study Group).

Lena Weiss, Sebastian Stintzing, Dominik Paul Modest et al. Jun 01, 2025 pp. 3543-3543 10.1200/jco.2025.43.16_suppl.3543

3543 Background: BRAF V600E mutation in metastatic colorectal cancer (mCRC) is associated with poor prognosis. Registrational appr...

Association of tumor extracellular matrix density with recurrence in invasive lobular carcinoma.

Roberta Dunn, Eduardo Peña, Sarah E. Pinder et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15162

e15162 Background: Invasive lobular carcinoma (ILC) is associated with a unique pattern of dissemination and higher risk of late relapse ( &gt; 10 years)...

Risk of intracranial hemorrhage with DOACs vs LMWH in patients with cancer-associated thrombosis and brain metastases.

Ali Mushtaq, Omer Ashruf, Alok A. Khorana et al. Jun 01, 2025 pp. 2034-2034 10.1200/jco.2025.43.16_suppl.2034

2034 Background: Intracranial hemorrhage (ICH) is a major and often devastating complication in patients with brain metastases requiring therapeutic antic...

Real-world outcomes of cytarabine consolidation in older patients with acute myeloid leukemia.

Dominika Dulak, Emily Geramita, Kristine Cooper et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18535

e18535 Background: Acute myeloid leukemia (AML) predominantly affects elderly patients. Standard of care treatment includes induction chemotherapy, follow...

Monotherapy of envafolimab in patients with high tumor mutational burden advanced solid tumors: Results from a phase II clinical trial.

Jian Li, Meiyu Fang, Jufeng Wang et al. Jun 01, 2025 pp. 2595-2595 10.1200/jco.2025.43.16_suppl.2595

2595 Background: Tumor mutational burden (TMB) has emerged as a predictive biomarker of immune checkpoint blockade response in cancers. Envafolimab, a hum...

Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and radiation (RT).

Shlomo A. Koyfman, Jenny HJ Lee, Laurent Mortier et al. Jun 01, 2025 pp. 6000-6000 10.1200/jco.2025.43.16_suppl.6000

6000 Background: Patients with high-risk LA cSCC are standardly treated with surgical resection followed by postoperative RT. Up to 30% of pts experience...

Clinical outcomes and molecular characteristics of patients with metastatic pancreatic ductal adenocarcinoma according to involved metastatic sites.

Mahmoud M.G. Yousef, Sali Albarouki, Ahmed Elhariri et al. Jun 01, 2025 pp. 4179-4179 10.1200/jco.2025.43.16_suppl.4179

4179 Background: It is well documented that Pancreatic ductal adenocarcinoma (PDAC) metastasize to the liver had worse outcome than to the lung, but the m...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page